X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Pharma: Safer havenů - Views on News from Equitymaster
 
 
  • PRINT
  • E-MAIL
  • FEEDBACK
  • A  A  A
  • May 14, 2004

    Pharma: Safer havenů

    The markets have been gyrating to and fro since the beginning of the year when the BSE-Sensex closed at the all time high of 6,194 on 14th Jan 2003. Since then, the benchmark index has gone nowhere. Although the Sensex has fallen considerably at about 9%, the concerning factor is the volatility over this period. What should an investor do at this juncture?

    Does this volatility mean no place for investors and they should keep away from the market for some time. The answer is, No! There are stocks, which have managed to outperform the benchmark indices amidst this volatility in the recent past. Though three to four months is not a time horizon that should draw comfort from, we believe that this out performance is because of fundamental reasons. We are talking about the pharma sector here.


    * Returns are calculated on Rs 100 invested on 1st Jan 2004

    To put things in perspective, the BSE Healthcare index is down 4% during the same period as against a 9% decline in the Sensex. If we look closely at the reason for the fall in the healthcare index, the key reason was on account of poor performance by heavyweights like Dr Reddy's, Pfizer and to an extent, Ranbaxy. At the same time, companies like Wockhardt, Aventis, Nicholas Piramal and GSK Pharma have outperformed the market by a fair margin. Apart from these stocks there some mid-cap stocks like Aurbindo pharma, Elder pharma and IPCA Labs have done quiet well.

    The gainers...
    Company (% gain*)
    Cipla 1.5%
    Nicholas Piramal 7.1%
    Glaxo 15.1%
    Aventis 15.8%
    Wockhardt 26.4%
    *since 1st Jan 2004
    Dr. Reddy's, that changed the face of Indian pharma companies, has suffered the most because of the some micro reasons like bad performance in the Indian markets and the adverse ruling of the 'Amolodipine Maleate' case in US. Pfizer has declined in the recent past owing to its poor performance, both on the topline as well as on the operating side, in FY04. However, we believe that the company has also taken additional charge on account of the restructuring exercise, which has set a solid platform for growing its revenues from a long-term perspective.

    The losers...
    Company (% loss*)
    Dr Reddy's -41.7%
    Pfizer -16.6%
    Ranbaxy -1.5%
    *since 1st Jan 2004
    Having looked at the gainers and the losers combined with the reasons for the same, what is the way forward? We have listed the key positives and negatives for the pharma sector below.

    Key positives...
    For MNCs...

    • The patent regime hold a host of opportunities for the MNC pharma companies regarding their product portfolio. They would be able to launch new products which will certainly increase their margins and also boost the topline.

    • Restructuring exercise done by most of the companies will start paying back and will again show up in the improved margins of the companies.

    For domestic majors...

    • Looking up foreign markets is the order of the day for the Indian companies. Bulk drugs, contract manufacturing, contract research and outsourcing will be the activities that will drive the growth for the Indian companies. Owing to the low cost and chemistry skills that Indian companies enjoy, gives them competitive advantage to be outsourcing hub for the world.

    • Big marketing network of some of the domestic pharma companies can be a platform for them to go aggressive on the domestic front. The marketing setup give them leverage in the Indian markets.

    • R&D efforts of some of the companies will pay in future but that is a long-term thing because it takes years to develop and launch new drugs.

    Investors have to remember that these are long-term fundamental drivers and are intact. However, exercise caution before taking any investment decisions, as not all players are likely to deliver consistent returns over the long-term.

     

     

    Equitymaster requests your view! Post a comment on "Pharma: Safer havenů". Click here!

      
     

    More Views on News

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    The Power of 5 Minutes (The 5 Minute Wrapup)

    Jun 16, 2017

    Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    More Views on News

    Most Popular

    Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

    Aug 7, 2017

    The data tells us quite a different story from the one the government is trying to project.

    Proxy Plays: A Smart Way to Bet on 'Off Limits' Companies(The 5 Minute Wrapup)

    Aug 4, 2017

    The small-cap space is full of small players that are clear proxies to great growth stories and Indian megatrends.

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

    Aug 7, 2017

    Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

    More
    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
     

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms

    S&P BSE HEALTHCARE


    Aug 17, 2017 09:33 AM

    S&P BSE HEALTHCARE 5-YR ANALYSIS

    COMPARE COMPANY

    MARKET STATS